Health
CDC warns of ‘dual mutant’ flu strain that could evade antiviral drugs: ‘Need to closely monitor’
A new “dual mutant” strain of H1N1 influenza could pose a threat in the U.S., according to the Centers for Disease Control and Prevention (CDC).
Details about the two strains, I223V and S247N, were published in the journal Emerging Infectious Diseases, which is published by the CDC.
At least two cases of the flu mutations have been confirmed in humans in the U.S., the agency announced on Wednesday.
COVID-FLU COMBO VACCINE SHOWS ‘POSITIVE’ RESULTS IN PHASE 3 TRIALS, MODERNA SAYS: A ‘TWO-FOR’ OPTION
The researchers identified a total of 101 samples of the “dual mutant” virus.
The concern is that these strains of flu have shown to be resistant to the antiviral medications that are typically used to treat the virus — notably Tamiflu (oseltamivir), the common flu medication from Switzerland-based Roche.
A new “dual mutant” strain of H1N1 influenza could pose a threat in the U.S., according to the Centers for Disease Control and Prevention. (iStock)
“The dual mutants that we tested retained susceptibility to other approved influenza antiviral drugs, including baloxavir,” the researchers wrote in the study findings.
CDC, WEBMD GIVE UPDATE ON CURRENT BIRD FLU OUTBREAK: ‘BE ALERT, NOT ALARMED’
“Our study highlights the need to closely monitor the evolution of dual mutants, because additional changes may further affect susceptibility to antiviral drugs or provide a competitive advantage over circulating wild-type viruses.”
The strains have been detected in 15 countries across five continents, but are mostly prevalent in Europe, the study found.
“The dual mutants that we tested retained susceptibility to other approved influenza antiviral drugs, including baloxavir,” the researchers wrote. (iStock)
The researchers determined that the mutations have been circulating globally since May 2023.
I223V and S247N were first tested by Hong Kong scientists, who published their findings in The Lancet Microbe in March 2024.
Those researchers also found that the mutant strains lessened the effectiveness of Tamiflu.
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, said it is “highly unusual” to see an influenza A strain (H1N1, which is a distant cousin of the Spanish flu, he noted) spreading throughout southern U.S. states at this time of year.
People who contract the flu can take antiviral medications to ease symptoms, the CDC stated, which is most important for high-risk patients. (iStock)
“Flu season is usually over by March,” Siegel told Fox News Digital. “Flu doesn’t spread as easily in hot, humid weather.”
He added, “This mutation worries me because the use of Tamiflu — especially in high-risk groups and the elderly — is really helpful at decreasing severity, and it looks like the reaction to it is less.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The doctor said he would still recommend using the drug, however, because it has some impact — “or consider other anti-flu drugs.”
Siegel also advised a vaccine booster for the elderly or those in high-risk groups.
The CDC recommends that everyone 6 months and older receives an annual vaccine during heightened flu spread. (iStock)
So far this season, the CDC estimates that there have been at least 35 million illnesses, 390,000 hospitalizations and 24,000 deaths from the flu, as published on the agency’s website.
The CDC recommends that everyone 6 months and older receives an annual vaccine during heightened flu spread.
For more Health articles, visit www.foxnews/health
People who contract the flu can take antiviral medications to ease symptoms, the CDC stated, which is most important for high-risk patients.
Fox News Digital reached out to Roche and to the CDC for additional comment.
Health
Brain aging may accelerate after cancer treatment, study suggests
NEWYou can now listen to Fox News articles!
Surviving cancer as a child or young adult may have a lasting impact on aging, new research suggests.
Researchers at the University of Rochester Medical Center looked at whether life-saving treatments, like chemotherapy and radiation, could speed up biological aging.
They also aimed to determine whether this age acceleration was linked to cognitive issues related to memory, focus and learning.
The team analyzed blood samples from a group of 1,400 long-term survivors treated at St. Jude Children’s Research Hospital, using epigenetic clocks — tools that estimate biological age by examining chemical tags on DNA.
Biological age is determined based on damage the cells accumulate over time, versus chronological age, which is measured by how long someone has been alive, according to scientists.
Biological age is determined based on the damage cells accumulate over time, according to scientists. (iStock)
“These well-established aging-related biomarkers have previously been associated with neurocognitive impairment and decline in older non-cancer populations, particularly in cognitive domains related to aging and dementia, such as memory, attention and executive function,” the study stated.
Most of the group consisted of acute lymphoblastic leukemia survivors, or Hodgkin lymphoma survivors. Participants were at least five years past their treatment, though some had survived for several decades.
They underwent neurocognitive testing to measure their attention span, memory and information processing speed.
CREATIVE HOBBIES KEEP THE BRAIN YOUNG, STUDY FINDS — HERE ARE THE BEST ONES TO PURSUE
Chemotherapy was found to have the greatest impact on aging acceleration. The study suggests the treatment can alter DNA structure and cause cellular damage.
CLICK HERE FOR MORE HEALTH STORIES
“It’s no surprise to find out that young people with cancer who have chemo early in life are affected in terms of long-term aging,” Dr. Marc Siegel, senior medical analyst for Fox News, told Fox News Digital.
Participants underwent neurocognitive testing to measure their attention span, memory and speed of information processing. (iStock)
Researchers also found that cellular aging was closely linked to cognitive performance, as survivors of a higher biological age had more difficulty with memory and attention.
“Chemo poisons and damages cellular function — hopefully the cancer cells more than normal cells, but there is a significant impact on normal cells as well,” said Siegel, who was not involved in the study.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“There is also something called ‘chemo brain,’ which causes at least temporary difficulty with memory, concentration, word finding and brain fog,” the doctor added.
The research team hopes to use these findings to focus on intervention efforts, specifically by determining when accelerated aging begins.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Young cancer survivors have many more decades of life to live,” lead study author AnnaLynn Williams, PhD, said in a press release. “If these accelerated aging changes are occurring early on and setting them on a different trajectory, the goal is to intervene to not only increase their lifespan, but improve their quality of life.”
The team hopes this research will help in the development of early intervention tools that aim to prevent cognitive decline. (iStock)
There were some limitations to the study. The researchers could not adjust for chronic health conditions or education because they are directly impacted by treatment.
Additionally, the study only looked at the survivors at a single point of time, so it could not directly prove causation.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The study was published in the journal Nature Communications.
Fox News Digital reached out to the researchers for comment.
Health
GLP-1 Drugs Linked to Osteoporosis and Gout: Here’s How To Stay Safe
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
Ozempic-style drugs could slash complication risks after heart attacks, research suggests
NEWYou can now listen to Fox News articles!
A popular class of weight-loss drugs may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked after a heart attack, according to a study published this week in Nature Communications.
The research, led by the University of Bristol and University College London, identified a biological brain-gut-heart signaling pathway.
This discovery appears to explain how GLP-1 drugs — which mimic glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite — protect heart tissue from a condition known as “no-reflow.”
“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, said in a press release.
“This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.”
In nearly half of all heart attack patients, tiny capillaries (blood vessels) remain narrowed even after the main blocked artery is cleared. (iStock)
This lack of blood flow increases the risk of heart failure and death within a year. GLP-1 medications could prevent this, according to the researchers.
How it works
When the GLP-1 hormone is released in the gut or administered as a drug, it sends a signal to the brain, which then sends a signal to the heart that switches on special potassium channels in tiny cells called pericytes.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
When these channels open, the pericytes relax, which allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle, the researchers noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The new study used animal models and cellular imaging to track how GLP-1 interacts with heart tissue. When the researchers removed the potassium channels, the drugs no longer protected the heart — confirming they play a key role.
The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments. (iStock)
The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to reduce tissue damage.
CLICK HERE FOR MORE HEALTH STORIES
The researchers noted several limitations, including that the study relied on animal models.
Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans.
While the study highlights the drug’s immediate benefits during a heart attack, it des not establish whether long-term use of these drugs provides a pre-existing level of protection. (iStock)
Additionally, while the study highlights the drug’s immediate benefits during a heart attack, it does not establish whether long-term use of the medication provides a pre-existing level of protection.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The research was primarily funded by the British Heart Foundation.
-
World1 week agoExclusive: DeepSeek withholds latest AI model from US chipmakers including Nvidia, sources say
-
Wisconsin4 days agoSetting sail on iceboats across a frozen lake in Wisconsin
-
Massachusetts3 days agoMassachusetts man awaits word from family in Iran after attacks
-
Massachusetts1 week agoMother and daughter injured in Taunton house explosion
-
Maryland5 days agoAM showers Sunday in Maryland
-
Florida5 days agoFlorida man rescued after being stuck in shoulder-deep mud for days
-
Denver, CO1 week ago10 acres charred, 5 injured in Thornton grass fire, evacuation orders lifted
-
Oregon7 days ago2026 OSAA Oregon Wrestling State Championship Results And Brackets – FloWrestling